Abstract. It remains undetermined whether there is an explicit association between the epidermal growth factor receptor (EGFR) gene mutation status and chemotherapy efficacy in non-small cell lung cancer (NSCLC) patients with advanced stages. Thus, the aim of the present retrospective study was to investigate the possible association between EGFR gene mutation status and the efficacy of first-line chemotherapy in patients with advanced NSCLC. In total, 52 patients who were diagnosed with NSCLC at Changzhou Tumor Hospital (Changzhou, China) from January 2015 to December 2018 were enrolled. All 52 patients received pemetrexed combined with platinum chemotherapy, for 21 days per cycle. After two cycles of treatment, the short-term clinical efficacy was assessed according to the Response Evaluation Criteria in Solid Tumours 1.1 guidelines. The objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) rate were calculated at the end of the study (December 31, 2019). These patients also underwent second-generation gene sequencing before the potential association between mutations in the EGFR gene and chemotherapy efficacy was analyzed. In this group of patients, 25 cases (48.1%) were found to be harboring EGFR gene mutation, whilst 27 cases (51.9%) expressed wild-type EGFR. After receiving the first-line chemotherapy regimen, the ORR was determined to be 36.5%, the DCR was 71.2%, whereas the PFS period was 207 days. Following first-line chemotherapy, the DCR of patients with EGFR mutations (52%) was higher compared with those in patients harboring the wild-type EGFR (22%). By contrast, the PFS (260 days) of patients with EGFR mutations was longer compared with those in patients harboring wild-type EGFR (100 days). These differences were statistically significant (P<0.05). Multivariate analysis revealed that EGFR gene mutation was an independent predictor of PFS in patients with advanced NSCLC (P<0.05). To conclude, data from the present study suggest that EGFR gene mutation has independent predictive value for the efficacy of first-line chemotherapy in patients with advanced NSCLC.

Introduction

Lung cancer currently ranks first in terms of mortality and morbidity compared with other types of malignancies worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer subtypes (1), where lung adenocarcinoma is one of the most common types of NSCLC. Since typical criteria of early symptoms for NSCLC remain unavailable, ~50% patients are diagnosed with advanced NSCLC on presentation (2,3). Therefore, treatment of advanced lung cancer forms an important branch of the lung cancer treatment development research field, which is also incidentally the one that has experienced an acceleration in research progress over the past decade. Platinum-containing dual-drug chemotherapy is the standard first-line chemotherapy regimen for NSCLC (4). In addition, it is also an important method for the treatment of advanced NSCLC (4). However, the rate of efficacy from this treatment remains at only ~30%, with a median survival time of 8-10 months and a one-year survival rate of ≤40%. Exploring
novel biomarkers that can be used to predict the sensitivity of patients with NSCLC to chemotherapy is therefore currently a topic of intense research.

Epidermal growth factor receptor (EGFR) is an important driver of lung adenocarcinoma. Mutations in the EGFR gene is one of the main predictors of the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs). For advanced or unresectable lung adenocarcinoma, EGFR gene status detection has become an important parameter for the selection of clinical treatment options (5-9). Previous studies have found that the EGFR gene status can also influence the efficacy of chemotherapy in patients with lung adenocarcinoma. However, the accuracy of its predictive power remains controversial. A number of studies have previously reported that patients harboring EGFR gene mutations can benefit more from chemotherapy compared with those harboring wild-type EGFR in advanced stages. In addition, the Individualized Plan for Academic Success System (IPASS) subgroup analysis revealed that patients with NSCLC harboring EGFR mutations are more likely to benefit from paclitaxel combined with carboplatin chemotherapy compared with patients with wild-type EGFR in the Asian and non-smoking lung adenocarcinoma subgroups (10). Yang et al (11) and Hotta et al (12) also previously revealed the survival benefits of EGFR gene mutations for patients with NSCLC. However, several previous clinical studies have reached different conclusions. Okamoto et al (13) and Qin et al (14) observed that there was no significant difference in the efficacy of chemotherapy between patients with advanced lung adenocarcinoma harboring EGFR gene mutations and those with wild-type EGFR. Similarly, Zhang et al (15) reported that EGFR mutations did not confer survival benefits to patients with NSCLC following a meta-analysis (15). By contrast, Zhu et al (16) and as well as other studies (17,18) determined that the survival time of patients with NSCLC containing wild-type EGFR may be longer compared with that in patients with EGFR mutations. Therefore, it remains unknown whether there is an association between the EGFR gene mutation status and chemotherapy efficacy, or whether EGFR mutations can confer chemotherapy efficacy and thereby prolong patient survival time. At present, since ambiguities in the currently available findings remain, additional evidence-based analysis is required.

Therefore, the present study statistically analyzed the clinical efficacy of first-line chemotherapy and its association with the EGFR gene mutation status in patients with advanced lung adenocarcinoma. The aim was to provide a theoretical basis for optimizing the therapeutic regimen for patients with advanced lung adenocarcinoma.

**Patients and methods**

**Patients.** Patients with pathologically diagnosed advanced lung adenocarcinoma at Changzhou Tumor Hospital (Changzhou, China) from January 2015 to December 2018, were selected as subjects in the present retrospective study. The Ethics Committee of Changzhou Tumor Hospital deemed the present study exempt from ethical approval due to its being retrospective in nature. The inclusion criteria were as follows: i) Lung adenocarcinoma was confirmed by cytology or histopathology analysis, where the foci could be measured definitively by computed tomography (CT) or magnetic resonance imaging (MRI); ii) stage III/IV confirmed by cytology or histopathology according to the lung cancer staging standard (8th edition) of the American Joint Committee on Cancer (AJCC) (19); iii) aged 18-75 years, with no sex discrimination; iv) the physical condition score according to the Eastern Cooperative Oncology Group guidelines (ECOG Performance Status) was 0-2 points (20); v) the blood samples for the examination of EGFR gene status were tested before treatment; vi) the routine blood test, liver and kidney function and electrocardiogram of patients were almost normal, such that no disease or dysfunction in the important organs could be detected; vii) after the diagnosis was confirmed, patients received standard first-line chemotherapy consisting of pemetrexed combined with cisplatin for ≥2 cycles, where their survival time was estimated to be ≥3 months; and viii) the patients or families of the patients consented to the content of this study and signed the informed consent form voluntarily. The exclusion criteria were as follows: i) Patients suffered from other malignant tumors and received other systemic antitumor treatment; ii) patients had a history of hypertension, hypertensive encephalopathy or uncontrolled hypertension at present; and iii) cases with incomplete clinical data.

**Chemotherapy.** In total, all 52 patients were treated with intramuscular injections of 500 mg/m² pemetrexed and 75 mg/m² cisplatin on day 1. Subsequently, 1 week before chemotherapy, the patients started to take 400 µg folic acid once a day until the end of chemotherapy, and received an intramuscular injection of 1 mg Vitamin B12 once every 9 weeks. In addition, 4.0 mg dexamethasone was administered 30 min before pemetrexed twice a day for 3 consecutive days. Those who had attained disease control were treated for ≥7 cycles, following which the curative effect was evaluated after ≥2 cycles were completed. Finally, the 52 patients were treated for 215 cycles, with an average of 4.13 cycles per patient.

**EGFR mutation test.** EGFR gene mutations were assayed by high-throughput sequencing technology, using Illumina next-generation sequencing (NGS) protocols, including Illumina TruSeq library preparation, Illumina sample indexing, and Illumina synthesis by sequencing (SBS) protocols as recommended by Illumina, Inc. Plasma samples were isolated from 10 ml fresh peripheral blood, from which circulating tumor DNA (ctDNA) (to note, the patients were all diagnosed with advanced lung adenocarcinoma and thus there was no surgical tissue, and only puncture specimens were used to confirm the type of cancer; therefore, EGFR gene mutation detection was based on the ctDNA of the peripheral blood of patients) was extracted using QIAamp Circulating Nucleic Acid Kit (cat. no. 55114; Qiagen China Co., Ltd.). The DNA quantity was measured on Qubit 3.0 fluorometer with dsDNA HS Assay Kit (Life Technologies; Thermo Fisher Scientific, Inc.). A minimum of 6 ng of DNA was used as input for the amplicon-based enrichment step. Subsequently, libraries were prepared using the KAPA Hyper Prep Kit (cat. no. KK8500; KAPA Biosystems; Roche Diagnostics) according to manufacturer's protocols. Then, fragmented DNA was subjected to end-repairing, A-tailing, indexed-adapter ligation, size
selection and PCR amplification. In brief, tumor DNA was amplified using either TruSeq kit or custom primers, and amplification products were confirmed with gel electrophoresis using a 2% agarose E-gel (Thermo Fisher Scientific, Inc.). Samples were indexed and pooled. The library fragments were then copied with the primer probe for 416 predefined cancer-associated genes, including all exons of EGFR. For targeted enrichment, indexed DNA libraries were pooled together for hybridization with customized xGen lockdown probes (Integrated DNA Technologies, Inc.) for 416 predefined cancer-relevant genes (21). Enriched libraries were amplified and subjected to NGS on Illumina Hiseq4000 platforms (Illumina, Inc.) to a targeted mean coverage depth of 3000X for ctDNA samples.

Observation and follow-up. Using the inpatient system of Changzhou Tumor Hospital, the clinical data of all cases were obtained and recorded, where the patients were followed up by outpatient, telephone or other means. Data that were collected at follow-up included the efficacy of chemotherapy, time to disease progression and time to mortality. The date of final follow-up was December 31, 2019.

Efficacy evaluation. According to the response evaluation criteria in solid tumors (RECIST) version 1.1 published in 2009 (22), all patients were evaluated at baseline before treatment, and after every 2 cycles of treatment. The efficacy evaluation was divided into complete response (CR), partial response (PR), sTable disease (SD) and progressive disease (PD). The objective response rate (ORR) was calculated as CR + PR, whereas the disease control rate (DCR) was calculated as CR + PR + SD. Progression-free survival (PFS) was defined as the time from the beginning of treatment to disease progression or death. Patients who did not progress or succumb to the disease at the end of the follow-up period were treated according to the follow-up deadline (December 31, 2019).

Statistical analysis. The statistical software SPSS 18.0 (SPSS, Inc.) was used for statistical analysis. Pearson's F test or Fisher's exact test were used to analyze the relationship among the EGFR gene status, clinical characteristics and chemotherapy efficacy. Kaplan-Meier survival curve and log-rank testing were used to analyze PFS, whereas Cox regression was used for multivariate analysis. Bilateral probability test was used in all statistical analyses, were P<0.05 was considered to indicate a statistically significant difference.

Results

Patients characteristics. As shown in Table I, amongst the 52 patients, 24 were male (46.2%) and 28 were female (53.8%). The age of the patients ranged from 36 to 75 years (median, 65±0.5), 21 were aged <65 years (40.4%), while 31 were aged ≥65 years (59.6%). In total, 16 patients were diagnosed with stage III (30.8%) and 36 patients were diagnosed with stage IV (69.2%). In total, PS scores of 50 patients were <2 (96.2%) whereas 2 patients scored 2 (3.8%). Furthermore, 14 patients were smokers (26.9%), while 38 cases were non-smokers (73.1%). A total of 25 patients were found with EGFR gene mutations (48.1%), whilst 27 patients were harboring wild-type EGFR (51.9%). The age, clinical staging, PS scores and

| Characteristics | No. of patients |
|-----------------|----------------|
| EGFR mutation   | EGFR wild-type |
| Total           | 25             | 27             | 52             |
| Sex             |                |                |                |
| Male            | 7              | 17             | 24             |
| Female          | 18             | 10             | 28             |
| Age, years      |                |                |                |
| <65             | 11             | 10             | 21             |
| ≥65             | 14             | 17             | 31             |
| Clinical stage  |                |                |                |
| III             | 8              | 8              | 16             |
| IV              | 17             | 19             | 36             |
| ECOG PS         |                |                |                |
| 0-1             | 23             | 27             | 50             |
| 2               | 2              | 0              | 2              |
| Smoking status  |                |                |                |
| Nonsmoker       | 16             | 22             | 38             |
| Smoker          | 3              | 11             | 14             |

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status.
smoking status of the patients were not found to be significantly different between the EGFR mutation and wild-type groups. However, the incidence of EGFR gene mutations in female patients was significantly higher compared with that in male patients (P=0.0115).

Effect of EGFR mutation on the response rate. Among the 52 patients, none achieved CR. By contrast, PR accounted for 36.5% (19/52), SD accounted for 34.6% (18/52) and PD accounted for 28.9% (15/52) (Table II). The ORR and DCR were calculated to be 36.5 and 71.2%, respectively. In 25 patients with EGFR gene mutation, the number of patients with PR, SD and PD were 13, 10 and 2, respectively. In 27 patients with EGFR wild-type, the number of patients with PR, SD and PD were 6, 8 and 13, respectively (Table II).

The incidence of PR (52.0 vs. 22.2%), SD (40.0 vs. 29.6%) and PD (8.0 vs. 48.1%) were observed at higher frequencies in patients with EGFR gene mutations compared with those in patients with wild-type EGFR (Table II). In addition, it was found that both the ORR (52.0 vs. 22.2%; P=0.0259) and DCR (92.0 vs. 51.9%; P=0.0019) were higher in patients with the EGFR gene mutation compared with those in patients with the wild-type EGFR. Association analysis of the ORR and DCR with other clinicopathological features was also performed (Table III). ORR was found to be associated with sex (P<0.0001), clinical stage (P=0.0491), ECOG-PS (38.0 vs. 0%) and smoking history (P=0.0019). However, no differences in ORR could be found when age (38.1 vs. 35.5%) was compared. The DCR was only found to be associated with sex (P=0.0024), ECOG-PS (74.0 vs. 0%) and smoking history (P=0.0063), but not with age and clinical staging. Neither of the two patients with a PS score of 2 achieved CR, PR and SD, thus the chi-square test was not applicable.

Effect of EGFR mutation on survival. The clinical cases were followed up until December 31, 2019. As shown in Table IV, the median PFS was 207 days in the 52 cases. The patients with EGFR gene mutations had a significantly longer median PFS compared with those in patients with wild-type EGFR (260 days vs. 100 days, P=0.0005; Fig. 1 and Table IV). The median PFS of the female patients (300 days) was significantly longer (P=0.0001) compared with those in male patients.

| Table II. Efficacy evaluation of patients with different EGFR gene status. |
|---------------------------------------------------------------|
| EGFR gene status | CR (%) (n=0) | PR (%) (n=19) | SD (%) (n=18) | PD (%) (n=15) |
|------------------|---------------|---------------|---------------|---------------|
| EGFR gene mutation (n=25) | 0 | 52.0 (13/25) | 40.0 (10/25) | 8.0 (2/25) |
| EGFR wild-type (n=27) | 0 | 22.2 (6/27) | 29.6 (8/27) | 48.1 (13/27) |

| Table III. Association between ORR, DCR and clinical features of 52 patients with NSCLC who were treated with chemotherapy. |
|---------------------------------------------------------------|
| Characteristics | Total No. of patients | ORR (χ²) P-value | No. of patients | DCR (χ²) P-value |
|------------------|---------------------|-------------------|----------------|------------------|
| EGFR status | 4.964 0.0259 | 25 13 | - 0.0019 |
| EGFR mutation | | 27 6 | |
| EGFR wild-type | | |
| Sex | - 0.0001 | 24 2 | - 0.0024 |
| Male | | 28 17 | |
| Female | | |
| Age, years | 0.0368 0.8478 | 21 8 | 0.0013 0.9713 |
| <65 | | 31 11 | |
| ≥65 | | |
| Clinical stage | 3.873 0.0491 | 16 9 | - 0.7522 |
| III | | 36 10 | |
| IV | | |
| ECOG PS | - 0.0019 | 50 19 | 7.474 0.0063 |
| 0-1 | | 2 0 | |
| 2 | | |
| Smoking status | - 0.0019 | 38 17 | |
| Nonsmoker | | 14 2 | |
| Smoker | | |

ORR, objective response rate; DCR, disease control rate; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PS, performance status.
(99 days). The median PFS of nonsmokers (255 days) was also significantly longer (P=0.0001) compared with that of smokers (90 days). The PFS of age, clinical staging and ECOG PS were not found to be statistically significant. Cox multivariate regression analysis was subsequently used to determine the independent influencing factors of PFS by incorporating multiple factors, such as the EGFR gene mutation status, sex, age, clinical staging, smoking history and ECOG PS. The results demonstrated that the EGFR gene mutation status [hazard ratio (HR)=2.056; 95% confidence interval (CI)=1.035-4.087; P=0.04] and female sex (HR=0.377; 95% CI=0.160-0.889; P=0.026) were independent prognostic factors of PFS in patients with NSCLC after receiving platinum-containing chemotherapy.

Table IV. Prognostic evaluation of PFS and clinical characteristics in all patients with NSCLC.

| Characteristics | No. of patients | Median PFS (days) | P-value | Multivariate analysis |
|-----------------|-----------------|-------------------|---------|-----------------------|
|                 |                 |                   |         |                       |
| EGFR status     |                 |                   |         |                       |
| EGFR mutation   | 25              | 260               | 0.0005  | 0.040                 |
| EGFR wild-type  | 27              | 100               |         | 2.056 (1.035-4.087)   |
| Sex             |                 |                   |         |                       |
| Male            | 24              | 99                | 0.0001  | 0.026                 |
| Female          | 28              | 300               |         | 0.377 (0.160-0.889)   |
| Age, years      |                 |                   | 0.1393  |                       |
| <65             | 21              | 256               |         | 1.598 (0.855-2.990)   |
| ≥65             | 31              | 161               |         |                       |
| Clinical stage  |                 |                   | 0.2402  |                       |
| III             | 16              | 186               |         | 0.953                 |
| IV              | 36              | 258               |         | 0.980 (0.504-1.907)   |
| ECOG PS         |                 |                   | 0.0512  |                       |
| 0-1             | 50              | 210               |         | 0.077                 |
| 2               | 2               | 90                |         | 1.434 (0.046-1.171)   |
| Smoking status  |                 |                   | 0.0001  |                       |
| Nonsmoker       | 38              | 255               |         | 0.467                 |
| Smoker          | 14              | 90                |         | 0.233 (0.543-3.787)   |

Independent variables with P<0.30 in the univariate analyses were included in the multivariate analysis of PFS in all patients after platinum-based chemotherapy. Cox's model was used for multivariate analyses with forward elimination. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Discussion

EGFR is one of the most studied molecular targets in lung cancer because its activity is closely associated with tumor growth, invasion and metastasis. EGFR is one of the most important drivers of NSCLC pathogenesis (23). EGFR gene mutations are major predictors of the efficacy of EGFR-TKIs in Asian patients with lung adenocarcinoma, where various studies have previously shown that patients with EGFR gene mutations tended to benefit more from concurrent treatment with EGFR-TKIs and standard first-line chemotherapy regimens (17,24-29). However, the relationship between the efficacy of chemotherapy and the EGFR gene status remains controversial.

Fang et al. (29) previously reported that first-line chemotherapy was more effective in patients with KRAS-negative EGFR gene mutations compared with those with wild-type EGFR, amongst 266 patients with advanced NSCLC (29). In addition, Kalikaki et al. (30) reported that patients with EGFR gene mutations were more sensitive to chemotherapy compared...
with that in patients with wild-type EGFR, amongst patients with advanced NSCLC. Multi-factorial analysis revealed that EGFR gene mutation was an independent predictor of PFS in patients with advanced lung adenocarcinoma. Lou et al (17) previously suggested that paclitaxel in combination with carboplatin as first-line chemotherapy was more effective in patients with EGFR gene mutations compared with patients with wild-type EGFR. However, Lee et al (31) found no significant associations between the EGFR gene mutation status and the efficacy of first-line chemotherapy. Another study from Japan also found that patients with EGFR gene mutations and advanced NSCLC who were treated with docorubicin chemotherapy exhibited worse outcome compared with patients with wild-type EGFR (32). The reasons for these ambiguous results may be due to the chemotherapeutic regimens and timing used not being completely uniform, such that the pathological types of lung cancer were not completely uniform and the sample sizes of a number of clinical studies were small. In addition, the EGFR gene mutation status may change during the course of the chemotherapeutic treatment period, which may also be associated with factors, such as region and ethnicity.

In the present study, 52 patients with advanced lung adenocarcinoma were tested for EGFR gene mutation status before the efficacy of first-line chemotherapy was analyzed retrospectively. The results revealed that for all patients with advanced lung adenocarcinoma treated with pemetrexed in combination with platinum-based regimens first line, the ORR, DCR and PFS of patients with EGFR gene mutations were superior compared with those of patients with wild-type EGFR, with the differences being statistically significant. Subsequently, Cox multivariate analysis showed that EGFR gene mutation was an independent predictor of PFS in patients with advanced lung adenocarcinoma, which is consistent with the results of previous studies (29,30).

In conclusion, following first-line chemotherapy for advanced lung adenocarcinoma, PFS was superior in patients with EGFR gene mutations compared with that in patients with wild-type EGFR. In addition, patients on pemetrexed-containing regimens had longer PFS regardless of EGFR gene mutations, which was more pronounced in those harboring EGFR mutations, suggesting that the EGFR gene mutation status can be an indicator for screening the pemetrexed-benefit population. However, the present study is a retrospective study that has a small sample size. Therefore, results found in the present study would need to be confirmed by prospective studies.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Science and Technology Project of Changzhou, Jiangsu Province (grant no. CE20205057), the Science and Technology Planning Project of Changzhou Health Bureau, Jiangsu Province (grant no. ZD201616), the Jiangsu Province Health Department Project (grant no. Z201616), the ‘333 Talents Training Project’ of Jiangsu Province and the ‘Talents Training Project’ for the Key Medical Innovation of Changzhou (grant no. 2016CZLJ02), the Youth Talent of Science and Technology Project of Changzhou Health Bureau, Jiangsu Province (grant no. QN202130), the Qingshui Tans Project of Changzhou Health Bureau, the Level I Talents Project of Changzhou Tumor Hospital Affiliated to Soochow University and the Level III Talents Project of Changzhou Tumor Hospital Affiliated to Soochow University.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LC, QQ, MZ, YZ, YP and YL contributed to the conceptualization, analysis and methodology of the study. LC and YL confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The Ethics Committee of Changzhou Tumor Hospital deemed the present study exempt from ethical approval due to it being retrospective in nature. All enrolled subjects or family members of the patients consented to the content of this study and signed the informed consent form.

Patients consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Hosomi Y, Morita S, Sugawara S, Kato T, Fukushima T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, et al: Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38: 115-123, 2020.
2. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsujii F, Linke R, Rosell R, Corral J, et al: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol 18: 1454-1466, 2017.
3. Xu CW, Wang G, Wang WL, Gao WB, Han CJ, Gao JS, Li Y, Wang L, Zhang LY, Zhang YP, et al: Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. Exp Ther Med 9: 880-884, 2015.
4. Xie Y, Liang J and Su N: Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 35: 446-449, 2015 (In Chinese).
5. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, et al: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 13: 539-548, 2012.
6. Rosell R, Carcereny E, Gervais R, Vergnerengre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.

7. Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R and Topolcan O: Pemetrexed versus erlotinib in the second-line treatment of patients with advanced-stage non-squamous NSCLC harboring wild-type EGFR gene. Anticancer Res 36: 447-453, 2016.

8. Lopes GL, Vattimo EF and Castro Junior Gd: Identifying activating mutations in the EGFR gene: Prognostic and therapeutic implications in non-small cell lung cancer. J Bras Pneumol 41: 365-375, 2015 (In English, Portuguese).

9. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0002). Ann Oncol 26: 1877-1883, 2015.

10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sundararajavong P, Han B, Mabrago B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.

11. Yang JC, Srimuninimit V, Ahn MJ, Ling CW, Tsai CM, Mok T, Orlando M, Puri T, Wang X and Park K: First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study. J Thorac Oncol 11: 370-379, 2016.

12. Hotta K, Kiura K, Toyooka S, Takigawa N, Kim YW, Nong J, et al: Correlation between EGFR mutation status and clinical outcomes of chemotherapy for advanced non-small cell lung cancer treated with platinum-based chemotherapy. Oncol Lett 10: 1135-1140, 2015.

13. Okamoto I, Aoe K, Tato T, Hosomi Y, Yokoyama A, Iinuma F, Kiura K, Hirashima T, Nishio M, Nogami N, et al: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 31: 1275-1282, 2013.

14. Qin N, Zhang Q, Wang J, Zhang H, Gu Y, Yang X, Li X, Lv J, Wu Y, Nong J, et al: Association between the epidermal growth factor receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 18: 131-137 (In Chinese).

15. Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z and Han JQ: EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysis. Lung Cancer 85: 339-345, 2014.

16. Zhu J, Zhang J, Chen M and Zhou CC: Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 35: 386-388 (In Chinese).

17. Lou N, Yang J, Yan H, Zhou Q, Liao R, Xu C, Huang Y, Yang X, Yang G and Wu Y: Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma. Zhonghua Yi Xue Za Zhi 94: 2337-2341, 2014 (In Chinese).

18. Park JK, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW and Heo DS: EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77: 433-437, 2012.

19. Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT: The eighth edition lung cancer stage classification. Chest 151: 193-203, 2017.

20. Oken MM, Creech RC, Torney DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5: 649-655, 1982.

21. Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, Tong X and Yu X: Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 7: 61755-61763, 2016.

22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gywther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.

23. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L and International Association for the Study of Lung Cancer International Staging Committee: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.

24. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffi LA, Yap JT, Janne PA, Johnson BE and Van den Abbeele AD: New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: Comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 195: W221-W228, 2010.

25. Huang W, Mao Y, Zhan Y, Huang J, Wang X, Luo P, Li L, Mo D, Liu Q, Xu H and Huang C: Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy. Oncol Lett 11: 723-730, 2016.

26. Kang X, Xiao HH, Song HQ, Jing XB, Yan LS and Qi RG: Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med 12: 362-374, 2015.

27. Tamura T, Kurishima K, Nakazawa K, Ishikawa S, Satoh H and Hizawa N: Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. Oncol Lett 10: 1135-1140, 2015.

28. Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Merger J, Schumann C, Serke M, Zaun S, Dietel M and Thomas M: EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: An observational study. Cancer Epidemiol Biomarkers Prev 24: 1254-1261, 2015.

29. Fang S, Wang Z, Guo J, Liu J, Li C, Liu L, Shi H, Liu L, Li H, Xie C, et al: Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Onco Targets Ther 7: 1185-1193, 2014.

30. Kalikaki A, Koutsopoulos A, Hatzidaki D, Tripak, Kontopoulos E, Stathopoulos E, Mavroudis D, Georgoulis V and Voutsina A: Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69: 110-115, 2010.

31. Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS and Bang YJ: Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small cell lung cancer. Jpn Clin Oncol 36: 344-350, 2006.

32. Yoshimasa T, Oura S, Ohta F, Hirai Y, Naito K, Nakamura R, Nishiguchi H, Hashimoto S, Kawagoe M and Okamura Y: Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J Thorac Oncol 6: 1658-1662, 2011.